Alnylam Pharmaceuticals (LTS:0HD2) Change In Payables And Accrued Expense : $115 Mil (TTM As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Alnylam Pharmaceuticals Change In Payables And Accrued Expense?

Alnylam Pharmaceuticals's Change In Payables And Accrued Expense for the quarter that ended in Sep. 2024 was $84 Mil. It means Alnylam Pharmaceuticals's Accounts Payable & Accrued Expense increased by $84 Mil from Jun. 2024 to Sep. 2024 .

Alnylam Pharmaceuticals's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was $81 Mil. It means Alnylam Pharmaceuticals's Accounts Payable & Accrued Expense increased by $81 Mil from Dec. 2022 to Dec. 2023 .

Alnylam Pharmaceuticals Change In Payables And Accrued Expense Historical Data

The historical data trend for Alnylam Pharmaceuticals's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alnylam Pharmaceuticals Change In Payables And Accrued Expense Chart

Alnylam Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

92.35

143.73

88.24

191.77

80.84

Alnylam Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															118.74	-38.67	-4.87	74.47	83.60

Alnylam Pharmaceuticals Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $115 Mil.

Alnylam Pharmaceuticals Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Alnylam Pharmaceuticals's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Alnylam Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alnylam Pharmaceuticals Inc (LTS:0HD2) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

ALNY:USA ALNY:Mexico DUL:Germany DUL:Germany A1LN34:Brazil

Address

675 West Kendall Street, Henri A. Termeer Square, Cambridge, MA, USA, 02142

Website

https://www.alnylam.com

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Alnylam Pharmaceuticals Headlines

No Headlines